New conjugate vaccines for the prevention of pneumococcal disease in developing countries

Drugs of Today

Volumn 47, Issue 3, 2011, Pages 207-214

  Ginsburg, A S ^a   Alderson, Mark R ^a  

^a PATH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

DEVELOPING COUNTRY; DRUG COST; DRUG SYNTHESIS; DRUG USE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; INDUSTRIALIZATION; LOWEST INCOME GROUP; PNEUMOCOCCAL INFECTION; REVIEW; SEROTYPE; IMMUNOLOGY;

DEVELOPING COUNTRIES; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 80051938182     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.3.1556471     Document Type: Review

References (33)

1. O'Brien, K.L., Wolfson, L.J., Watt, J.P. et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
2. Pilishvili, T., Lexau, C., Farley, M.M. et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1): 32-41.
3. Ray, G.T., Whitney, C.G., Fireman, B.H., Ciuryla, V., Black, S.B. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006, 25(6): 494-501.
4. Poehling, K.A., Lafleur, B.J., Szilagyi, P.G. et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics 2004, 114(3): 755-61.
5. Grijalva, C.G., Poehling, K.A., Nuorti, J.P., Zhu, Y., Martin, S.W., Edwards, K.M., Griffin, M.R. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006, 118(3): 865-73.
6. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008, 57(6): 144-8.
7. Lynch, J.P., 3rd, Zhanel, G.G. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009, 30(2): 189-209.
8. Weatherholtz, R., Millar, E.V., Moulton, L.H., Reid, R., Rudolph, K., Santosham, M., O'Brien, K.L. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis 2010, 50(9): 1238-46.
9. Rozenbaum, M.H., Sanders, E.A., van Hoek, A.J. et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010, 340: c2509.
10. Techasaensiri, C., Messina, A.F., Katz, K., Ahmad, N., Huang, R., McCracken, G.H., Jr. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas. Pediatr Infect Dis J 2010, 29(4): 294-300.
11. Pichichero, M.E., Casey, J.R. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007, 298(15): 1772-8.
12. Hsu, K.K., Shea, K.M., Stevenson, A.E., Pelton, S.I. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J 2010, 29(4): 289-93.
13. Reinert, R., Jacobs, M.R., Kaplan, S.L. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010, 28(26): 4249-59.
14. van Gils, E.J., Veenhoven, R.H., Hak, E. et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA 2010, 304(10): 1099-106.
15. Choi, E.H., Kim, S.H., Eun, B.W., Kim, S.J., Kim, N.H., Lee, J., Lee, H.J. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008, 14(2): 275-81.
16. Cheung, Y.B., Zaman, S.M., Nsekpong, E.D., Van Beneden, C.A., Adegbola, R.A., Greenwood, B., Cutts, F.T. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. Pediatr Infect Dis J 2009, 28(11): 990-5.
17. Cutts, F.T., Zaman, S.M., Enwere, G. et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365(9465): 1139-46.
18. Johnson, H.L., Deloria-Knoll, M., Levine, O.S. et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010, 7(10): e1000348.
19. Pollabauer, E.M., Petermann, R., Ehrlich, H.J. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine 2009, 27(11): 1674-9.
20. Pavia, M., Bianco, A., Nobile, C.G., Marinelli, P., Angelillo, I.F. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009, 123(6): e1103-10.
21. World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines-proposed replacement of TRS 927, Annex 2, ECBS, 19 to 23 October 2009. http://www.who.int/biologicals/areas/ vaccines/pneumo/Pneumo-final-23APRIL-2010.pdf. Accessed January 27, 2011.
22. Yeh, S.H., Gurtman, A., Hurley, D.C. et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010, 126(3): e493-505.
23. Esposito, S., Tansey, S., Thompson, A. et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010, 17(6): 1017-26.
24. Prymula, R., Schuerman, L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009, 8(11): 1479-500.
25. Prymula, R., Peeters, P., Chrobok, V. et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367(9512): 740-8.
26. Indrawati, L., Skinner, J., Winters, M., et al. Development of an infant rhesus monkey model for preclinical evaluation of a novel 15-valent pneumococcal polysaccharide protein conjugate vaccine. 7th Int Symp Pneumococci Pneumococcal Dis (March 14-18, Tel Aviv) 2010.
27. A study of pneumococcal conjugate vaccine (V114) compared to a marketed vaccine (Study V114-003-00) (NCT01215188). ClinicalTrials.gov Web site, Accessed January 27, 2011.
28. PATH. Pneumococcal Vaccine Project. http://www.path.org/projects/ pneumococcal-protein-vaccine-project.php. Accessed January 27, 2011.
29. World Health Organization. Target Product Profile (TPP) for the Advance Market Commitment (AMC) for Pneumococcal Conjugate Vaccines. February 22, 2008. http://www.who.int/immunization/sage/target-product-profile.pdf. Accessed January 27, 2011.
30. Michon, F., Fusco, P.C., Minetti, C.A. et al. Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein. Vaccine 1998, 16(18): 1732-41.
31. Cherian, T. WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resourcepoor developing countries, 26-27 October 2006, Geneva. Vaccine 2007, 25(36): 6557-64.
32. Jadhav, S., Datla, M., Kreeftenberg, H., Hendriks, J. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine 2008, 26(13): 1611-5.
33. GAVI Alliance. Advance Market Commitments (AMCs). http://www. gavialliance.org/vision/policies/in-financing/amcs/index.php. Accessed January 27, 2011.